FDA Decision Alert
The FDA
Peripheral and Central Nervous System Advisory Committee is scheduled
to meet on Wednesday to provide
Medical Meeting Alert
Two major medical meetings are taking place within the next five days that will direct investor attention to several
companies
FDA Decision Analysis: SCIO
The FDA advisory committee for cardiovascular and renal drugs met Friday and unanimously approved the use of Scios’ new drug Natrecor
FDA Alert
Look for movement in SCIO’s stock price on Friday
as the FDA votes on approval
Biotech in 2001
This year will bring
more companies to the land of profitability because of increasing demand for new
pharmaceutical treatments and rapidly advancing technology
Patience Is The Virtue In Biotechnology
Despite the malaise and gloom hanging over the markets today, particularly on the technology side of
the Nasdaq, I am very optimistic about biotechnology
Scanning The Biotech Landscape
Where will the action be in the near term?
Y2K: The Year Of The Genomic IPO
This year has already seen a record number of biotechnology IPOs, with over half focused on genomic technology. To date, 49 new biotechnology companies have gone public,
Human Stem Cells: The Body’s Fountain Of Youth?
Recently the US government announced that it was easing restrictions on the use of stem cells in medical research,
which generated much interest in companies on the cusp of this promising arena.
Alzheimer’s Disease: A Growing Market Ready To Bear Fruit
Why are so many major pharmaceutical and biotech companies feverishly racing to develop new treatments for this growing disease?
Profiting From The Human Genome
As Celera
is poised to announce its completion of the entire human genome, the worldwide $350 billion-plus pharmaceutical market is there for the taking.
Bright Future For New Breed Of Alzheimer’s Drugs
Until recently, Alzheimer’s disease was a mystery to physicians and researches alike. But this year has seen an explosion in research findings regarding Alzheimer’s disease that has many companies geared up to find the first blockbuster treatment. We’ll look at who’s poised to strike first in this market.